AI assistant
Take Solutions Ltd Earnings Release 2021
60381_rns_2021-02-12_65a1eccf-85a9-4d4e-a64c-2ffd6f23cd4d.pdf
Earnings Release
Open in viewerOpens in your device viewer
TECHNOLOGY ANALYTICS KNOWLEDGE ENTERPRISE
February 12, 2021
TAKE/BSE/2020-21
The Manager Dept. of Corporate Services-Listing Bombay Stock Exchange Limited, P. J. Towers, Dalal Street, Mumbai - 400001
TAKE/NSE/2020-21
The Manager-Listing Department National Stock Exchange of India Limited Exchange Plaza, Sandra - Kurla Complex, Sandra (East), Mumbai - 400051
Dear Sir/Madam,
Sub: Earning Release Ref: NSE Scrip, Code: S32890 & BSE Scrip Code: TAKE
We are pleased to enclose an earnings release for your reference and record.
Kindly take ncte of the same.
Thanking you.
Yours sincerely, For TAKE Solutions Limited
f j/VV.itMtv\
Srinivasan P Company Secretary
Encl: As above.
TAKE SOLUTIONS LIMITED
Registered & Corporate Office : No: 27, Tank Bund Road, Nungambakkam, Chennai 600 034 CIN: L63090TN2000PLC046338; GSTIN: 33AABCT3684M1Z0 Tel: +91 44 6611 0700/01
www. takesolutions. com
UNCERTAIN.
Sure to REBOUND. Q3 FY21 Earnings Release
Quarter Ended December 31, 2020
Business Highlights – Significant Traction
Business Highlights – Results of focused business development efforts
Sourced Over $7mn of business from a global pharma (rare disease focus)
Increased Annual Contract Value By 23% for a long-term client (top 5 Pharma)
Successfully delivered COVID-19 studies in APAC for a large specialty pharma, leading to Additional Business In The US Market
Added 6 New Members to our proprietary industry forums "NETS" in Q3
Won More Than $5mn Of New Business from a single account (top 5 specialty Pharma)
The CRO Industry Is At An Inflection Point – We are poised to TAKE advantage
COVID-19 HAS BROUGHT A MUCH-NEEDED IMPETUS TO DIGITAL TRANSITION
The global lockdowns have made the industry embrace the full potential of digital health tech like wearables, sensors and apps
THE INDUSTRY IS UNDERGOING A STRUCTURAL TRANFORMATION
Restructuring of the clinical trial landscape has begun. Returning to the traditional models is highly unlikely
ACCELERATED TRIALS WITH RIGORUS STANDARDS IS THE NEED OF THE HOUR
Technology platform-based services will be instrumental in rising to meet the demands of the current crisis, without compromises.
COVID-19 Has Changed Clinical Trials Forever Technology-enabled services is the new normal
OUR HEADSTART
TAKE has been investing in End-to-End Technology stack for over a decade.
Domain Expertise – Showcasing Thought Leadership
Q3 – Moderate Recovery & Healthy Outlook
Q3 results witnessed a moderate paced recovery and turned EBITDA positive
Confidential - Property of TAKE Solutions- 2021 7
Quarterly Performance of the Continuing Business*
73.82 Period Average Rate 73.09 Period Closing Rate Q3 FY21 74.32 Period Average Rate 73.70 Period Closing Rate Q2 FY21 71.15 Period Average Rate 71.33 Period Closing Rate Q3 FY20 Dollar Rates
* Continuing Ops Figures - Excluding the impact of business divested (discontinued operation – supply chain) during the quarter Q2 FY21.
Profit & Loss account
| AllfiguresinINRMn | |||||
|---|---|---|---|---|---|
| Particulars | FY20 | Q1FY21 | Q2FY21 | Q3FY21 | YTDFY21 |
| fromRevenueOperations | 22129, | 1659, | 2181, | 2164, | 6003, |
| OtherIncome | 264 | 33 | 7 | 96 | 136 |
| TotalIncome | 22393, | 1692, | 2187, | 2260, | 6139, |
| Expenses | |||||
| ofCostRevenue | 6616, | 523 | 726 | 537 | 1787, |
| Employeebenefitsexpenses | 1867, | 2871, | 3981, | 1911, | 3876, |
| FinanceCosts | 413 | 102 | 94 | 94 | 290 |
| andDepreciationamortisation | 1669, | 303 | 289 | 283 | 876 |
| OtherExpenses | 6638, | 1874, | 796 | 382 | 3052, |
| TotalExpenses | 22522, | 4090, | 3304, | 2487, | 9881, |
| /(Loss)Profitbeforetax | (129) | (2398), | (1116), | (228) | (3742), |
| TaxExpense | |||||
| Currenttax | 415 | 27 | 20 | 9 | 56 |
| Deferredtax | (417) | (15) | 19 | 20 | 24 |
| Short/(Excess)forearlierProvsionyears | (17) | - | - | - | - |
| /Profit(Loss)fortheyear | (109) | (2409), | (1156), | (256) | (3821), |
Earnings Conference Call Represented By
Srinivasan H.R. Vice Chairman and Managing Director
Shobana N.S Executive Director
Lalit Mahapatra Chief Financial Officer
Dr Ayaaz Hussain Khan Global Head, Generics
Sowmya Kaur Clinical Head for APAC
Conference Call Details
Time: 16:30 (IST) | Date: February 12th, 2021, Please dial the below number
at least 5-10 minutes prior to the conference schedule to ensure that you are connected to the call-in time.
International Dial In (Toll Free) Hong Kong: 800 964 448 Singapore : 800 101 2045 UK : 080 8101 1573 USA : 186 6746 2133 International Dial In (Toll) Hong Kong: 85 230 186 877 Singapore : 65 3157 5746 UK : 44 203 478 5524 USA : 132 3386 8721 Diamond Pass registration Link
Universal Access Number: +91 22 6280 1144 / +91 22 7115 8045 Local Access Number: +91-7045671221 (Available all over India)
Call Co-ordinator
Mr. Sriraam Rathi: Phone: +91 22 6637 7574, e-mail: [email protected] Mr. Vinay Bafna: Phone: +91 22 6637 7339, e-mail: [email protected]
For any clarification, please contact: Mr. Rushad Kapadia: Phone: +91 22 6637 7334, e-mail: [email protected] Ms. Divya Purohit: Phone: +91 22 6637 7454, e-mail: [email protected]
THANK YOU
For more details, please contact: [email protected]
Confidential - Property of TAKE Solutions- 2021 13 www.takesolutions.com